Browsing by Subject "Lungs--Cancer"
Now showing items 1-5 of 5
-
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
(Brac University, 2023-12)Researchers must prioritize non-small cell lung cancer clinical research due of its high mortality. Ongoing endeavors are being made to improve the accessibility, evaluation simplicity, and prediction accuracy of endpoints ... -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
(Brac University, 2023-03)The American Cancer Society estimates that lung cancer is the most common type of cancer and nearly 25% cancer deaths result from lung cancer, of which three subtypes account for 80% of cases. This is the rationale behind ... -
Lung cancer immunosuppression and therapeutic targeting of myeloid- derived suppressor cells
(Brac University, 2022-02)Myeloid derived suppressor cells or MDSC are immune cells derived from the common myeloid progenitor which is able to develop erythrocytes , platelets or other granulocytes .They are separated into two different subsets ... -
An overview of the clinical management and challenges of treatments for the patients diagnosed with COVID-19 and lung carcinoma
(Brac University, 2021-09)During the COVID-19 disease outbreak, the main objective of lung carcinoma treatment is to reduce the risk of contamination to patients and workers while simultaneously controlling all life-threatening elements of the ... -
Targeted treatment in patients with non-small cell lung cancer: Use of Bevacizumab and its Biosimilars
(Brac University, 2021-04)Angiogenesis is one of the pivotal factors contributing to the development and metastasis of non small cell lung cancer which is one of the most commonly diagnosed types of lung cancer. Bevacizumab, a monoclonal antibody ...
